US 12,251,438 B2
Immunogenic compositions of polysaccharide-protein pegylated compounds
Subhash V. Kapre, Redmond, WA (US); and Anup K. Datta, Renton, WA (US)
Assigned to Inventprise, Inc., Redmond, WA (US)
Filed by Inventprise, LLC, Redmond, WA (US)
Filed on Jul. 4, 2022, as Appl. No. 17/857,110.
Application 17/857,110 is a continuation of application No. 16/984,145, filed on Aug. 3, 2020, granted, now 11,376,323, issued on Jul. 5, 2022.
Application 16/984,145 is a continuation of application No. 16/593,282, filed on Oct. 4, 2019, granted, now 10,729,763, issued on Aug. 4, 2020.
Application 16/593,282 is a continuation in part of application No. 16/004,743, filed on Jun. 11, 2018, granted, now 10,688,170, issued on Jun. 23, 2020.
Claims priority of provisional application 62/517,905, filed on Jun. 10, 2017.
Prior Publication US 2023/0115072 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/385 (2006.01); A61K 39/09 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/385 (2013.01) [A61K 39/092 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/627 (2013.01)] 31 Claims
 
1. A method for protection against an infection by Streptococcus pneumoniae comprising:
providing an immunogenic composition comprising a first group of monovalent capsular polysaccharides and a second group of bivalent or multivalent capsular polysaccharides wherein:
the first group of monovalent capsular polysaccharides comprise polysaccharides of S. pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; and
the second group of bivalent or multivalent capsular polysaccharides comprising two or more polysaccharides selected from one or more of the groups consisting of S. pneumoniae serotypes 6A/6B/6C/6D, S. pneumoniae serotypes 9V/9N/9A/9B, S. pneumoniae serotypes 15B/15A/15C, and S. pneumoniae serotypes 19A/19F, wherein:
the first group of monovalent capsular polysaccharides are each covalently coupled to a first PEG linker which is couple to a first carrier protein, and
the second group of bivalent or multivalent capsular polysaccharides are each covalently coupled to a second PEG linker which is coupled to a second carrier protein; and
administering a dose of the immunogenic composition to a subject.